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Abstract. With the increasing interest in post-GWAS research which represents a transition from 
genome-wide association discovery to analysis of functional mechanisms, attention has been lately 
focused on the potential of including various biological material in epidemiological studies. In particular, 
exploration of the carcinogenic process through transcriptional analysis at the epidemiological level opens 
up new horizons in functional analysis and causal inference, and requires new designs together with 
adequate analysis procedures. In this article, we present the post-genome design implemented in the 
NOWAC cohort as an example of a prospective nested case-control study built for transcriptomics use, 
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and discuss analytical strategies to explore the changes occurring in transcriptomics during the 
carcinogenic process in association with questionnaire information. We emphasize the inadequacy of 
survival analysis models usually considered in GWAS for post-genome design, and propose instead to 
parameterize the gene trajectories during the carcinogenic process. This novel approach, in which 
transcriptomics are considered as potential intermediate biomarkers of cancer and exposures, offers a 
flexible framework which can include various biological assumptions. 
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1  Introduction  
Classical epidemiology investigates the association between environmental variables and a disease of 
interest at the population level. During the past decades, research has moved to molecular epidemiology 
which incorporates biological material together with more classical questionnaire data. In particular, the 
development of microarray technologies has made possible agnostic studies including genome-wide data 
[1]. Prospective GWAS (Genome Wide Association Studies) analyse the association between genomics 
data, in particular SNPs (Single Nucleotide Polymorphisms), and the time of appearance of a disease 
through prediction and risk estimation. 
To address the important issue of bias selection of cases and controls in epidemiology, cohort designs 
were established in the 50’s whereby a large number of individuals are recruited at the beginning of the 
study and followed either individually or through a register. The cases arising during the follow-up can be 
compared with the controls in the cohort in an unbiased way. When the variables of interest are expensive 
or complicated to collect, a limited number of controls are randomly selected in the cohort for each case, 
termed a nested case-control design, and the analysis is based on measurements of the variables for nested 
cases and selected controls.  
The statistical analysis of prospective GWAS is usually based on survival analysis models which 
model failure time as a function of genomics and lifestyle variables. In particular, the Cox proportional 
hazard rate model [2], which is the corner stone of many GWAS, was developed in the early 70’s in order 
to estimate relative risk without computing the time baseline through the minimization of a partial 
likelihood. Different types of penalization have been introduced to compensate for large dimension 
covariates [3, 4]. Thomas [5] adapted the likelihood to integrate nested case-control data. Furthermore, a 
huge number of statistical articles propose generalizations of the Cox model, in particular to include time-
varying coefficients [6, 7] or covariates measured with errors [8]. 
With the increasing interest in post-GWAS research which represents a transition from genome-wide 
association discovery to analysis of functional mechanisms, attention has been lately focused on the 
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potential of including other biological material (mRNA, miRNA, methylation etc) in epidemiological 
studies to move from prediction and risk estimation to causal inference [9]. To address these novel issues, 
cohorts including various type of biological material have been established. In particular, the Norwegian 
Women And Cancer (NOWAC) post-genome cohort [10] which incorporates transcriptomics 
measurements (mRNA) in peripheral blood together with lifestyle information collected in a prospective 
design offers the opportunity to explore the functional changes associated with the carcinogenic process 
on transcriptional outputs . 
In this paper, we will discuss analytical strategies to explore the changes occurring in transcriptomics 
in peripheral blood during the carcinogenic process in association with questionnaire information based 
on a prospective nested case-control design. This design differs from the more classical genome-wide 
studies, which can be classified in two categories. Cross-sectional or hospital case-control studies 
including transcriptomics or genomics data, which do not involve a time aspect, [11] and prospective 
GWAS including genomics data, in which individuals are followed over time. The post-genome design 
which incorporates transcriptomics data in a prospective design represents a hybrid between these two 
categories.  
Since the post-genome design shows high similarities with the classical prospective GWAS, 
epidemiologists could be tempted to apply statistical methods developed for GWAS nested case-control 
data to this new type of study. Nevertheless, the distinct nature of the association between cancer and 
genomics in prospective GWAS, and cancer and transcriptomics in the post-genome cohort calls for a 
different statistical approach. Instead of the survival analysis model usually considered in GWAS: 
                                    P[T|G,E]    (1) 
with T the time of failure, G genomics data, and E environmental exposures, we propose to parameterize 
the trajectory of the gene expression during the carcinogenic process: 
                                   P[G|T,E]    (2) 
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with T the time before diagnosis, G transcriptomics data and E environmental exposures. We will 
emphasize that despite the connection between (1) and (2), the statistical approaches based on these two 
quantities target a different nature of associations between genes and cancer, and that the second approach 
seems more suitable and more directly interpretable to explore the functional changes occurring in gene 
expression during the carcinogenic process.  
2  Transcriptomics in a prospective nested case-control design 
We present the post-genome design implemented in the NOWAC post-genome cohort [10] as an example 
of a prospective nested case-control study built for transcriptomics use. The NOWAC post-genome cohort 
includes 49,633 women born during 1943-57 who gave a blood sample and filled-in a detailed 
questionnaire regarding various aspects of their lifestyle at the beginning of follow-up. The blood samples 
were stored in conditions that preserve the mRNA (PAX-tubes). The women are followed by linkage with 
the Norwegian Cancer Register, and for each woman in the cohort diagnosed with cancer, a control is 
randomly picked-up among the healthy women with same age in the cohort (Figure 1). Blood samples 
from both case and control are analysed on the same Illumina WG6 or HT12 BeadChip. During 7 years of 
follow-up, 739 incident breast cancer were identified.  
 
2.1  Exploration of functional changes in peripheral blood transcriptome 
A challenging issue raised by post-genome research is the exploration of functional changes associated 
with carcinogenesis. In this context, the NOWAC post-genome cohort explores the potentiality of using 
transcriptomics as biomarkers of the carcinogenic process, by examining how gene expression is affected 
by carcinogenesis.  
Let us consider a hypothetical example to illustrate our approach. For a given case, assume that, the 
mean expression of a gene g has the trajectory presented on the first column of Figure 2. The ideal design 
to recover the gene trajectory would consist of longitudinal data with multiple time measurements for the 
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same individual. But this type of data, available in clinical studies, would be much more expensive and 
complicated to collect in a cohort. Therefore, the measurements taken at different times before diagnosis 
on different cases are incorporated to mimic a longitudinal design. Assume that gene g has the five 
trajectories presented on the second column of Figure 2 (dotted lines) for five cases in the cohort. Then, 
single measurements of gene expression for each case at different times before diagnosis enable recovery 
of the trend of the trajectory (third column of Figure 2). 
In the hypothetical example above, the trajectories of gene g are similar for all individuals. But, in 
epidemiological studies, gene expression is subject to important variations from one individual to the 
other. Our goal is to detect a general trend due to carcinogenesis in all cases or in a pre-defined subset of 
cases (individual with a given type of cancer, etc), but high variations between individuals will dilute the 
effect of carcinogenesis. Several epidemiological studies have previously assessed the effect of 
environmental exposures on gene expression [12-14] Therefore, the exposure variables extracted from the 
questionnaire are incorporated in the analysis in order to partially correct individual variations and 
increase the sensitivity of detection of genes involved in the carcinogenic process.  
 
 
2.2  From GWAS to post-genome design: a different point of view 
The point of view adopted in classical prospective GWAS studies is the following: given the values of 
some covariates (genomics and environmental), what is the risk of developing a cancer at some time?  In 
this context, genomics and exposures variables are considered as risk factors for cancer.  
In the post-genome design, we analyse how transcriptomics is affected by both carcinogenesis and 
exposures. Transcriptomics are assumed to contain some information which could potentially represents 
intermediate biomarkers of cancer and exposures. This change in point of view is illustrated in Figure 3. 
The first column presents the classical nested case-control point of view: we observe the time of failure of 
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all individuals given some variables. The second column presents the novel point of view adopted for the 
post-genome design: the time of reference is not the beginning of the study but the time of diagnosis. 
 
 
Role of exposures. The post-genome design includes two types of environmental or lifestyle exposures 
extracted from the questionnaire: 
(i) Exposures possibly associated with breast cancer (carcinogens): in particular, risk factors related to 
the history of the individual (age of first pregnancy, use of hormone replacement therapy etc.). 
(ii) Exposures not associated with breast cancer but which may affect gene expression: in particular, 
diet, consumption of tobacco, use of medication, at time of blood sample.  
Classical epidemiological studies which focus on prediction and risk estimation only includes the 
exposures from the first category. Conversely, in post-genome studies, the second type of exposures are 
considered as sources of noise on transcriptional outputs and should be included in the analysis to 
improve sensitivity. Thus, the study of gene trajectories in transcriptomics would be optimized by 
incorporation of exposures that affect gene expression, regardless of their association to cancer. 
 
Role of controls. In classical nested case-control GWAS, controls are considered as censored 
observations at the time of failure of the matched case: if the control is selected at time t, the only 
information used is that the control was not diagnosed with cancer before t. Inclusion of controls in the 
design is essential in order to identify risk factor and estimate relative risks.  
The situation is different in post-genome cohort: a priori, the exploration of gene trajectories as a 
function of time to diagnosis would not require the inclusion of controls. Nevertheless, controls are 
considered as references in order to remove technical and age effects. Indeed, the pairs are matched by 
age, therefore considering the difference of log-expression between matched case and control should 
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remove an additive effect of age on gene expression. Similarly, since matched case-control pairs are 
analysed on the same BeadChip, the case-control difference reduces technical noise.  
However, if a control is close to diagnosis at time of matching, the carcinogenesis effect in the case 
transcriptome could be eliminated by the case-control difference. Thus, our analysis is based on the 
implicit assumption that the control is not in the "final phase" of carcinogenic process at time of blood 
sample. In the NOWAC post-genome cohort which explores carcinogenesis 7 years before diagnosis, this 
assumption amounts to considering that the controls will remain cancer-free 7 years after the blood 
sample. This approximation is reasonable for two reasons: First of all, the incidence rate along the 7 years 
of follow-up is small (739/49633 = 0.015) so only a few controls would be implicated. Moreover, the 
follow-up through the Norwegian Cancer Register enables removal of the pair if the control develops a 
cancer in the future.  
3  Statistical approach for transcriptomics in nested-case control 
prospective design 
In the previous section, we underlined the differences between classical prospective GWAS and the post-
genome design. The novel challenges raised by the transition from risk estimation and prediction from 
genomics to exploration of functional changes on transcriptomics naturally lead us to consider 
longitudinal models (2) with G in alternative to the classical survival analysis models (1) used in GWAS. 
Nevertheless, considering survival analysis models to detect genes whose expression changes during the 
carcinogenic process could appear natural: if the expression of a gene depends on time to diagnosis, this 
gene should be involved in (1). Nevertheless, even if models (1) and (2) are related through Bayes 
formula: 
  
they would be equivalent only under the knowledge of distributions P[T|E] and P[G|E], which are not 
available. In this section, we illustrate why the survival analysis models developed for genome-wide 
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nested case-control design, in particular the Cox model, cannot be directly adapted to the post-genome 
design, and we present an alternative approach based on a gene-by-gene model.  
3.1  Are survival analysis models relevant for post-genome design?  
Semi-parametric models. Survival analysis models parameterize a time of failure T (in our context, the 
follow-up time) as a function of a vector of variables X. The analysis in nested case-control design has 
been mainly focused on semiparametric models. Zheng et al [15] propose a procedure of estimation 
adapted to the nested case-control design for a very flexible model including additive and multiplicative 
proportional effects. The procedure for the additive part of the model requires knowledge of the history of 
the covariate, i.e. the value of the covariates at any time before T. This information is not available for 
transcriptomics variables, which exclude the use of the additive hazard model in our context. Conversely, 
multiplicative hazard models can be estimated from a unique observation of the covariates. Let us 
examine their relevance for post-genome data.  
Cox proportional hazard model for nested case-control design. The Cox model (see Figure 4) is one of 
the most popular model in prospective nested-case control studies. The hazard rate, defined as the risk of 
occurrence of an event just after a time t given that it did not occurs before t is the product of a baseline 
hazard rate function and the exponential of a linear combination of covariates. This model, originally 
developed by Cox [2] does not rely on a biological modeling, but has been designed to address a specific 
statistical goal: the relative risks can be computed from right-censored observations without estimating the 
baseline, via a partial likelihood based on the ranking of the failure times.  
Thomas [5] adapted the partial likelihood technique to nested case-control design, and theoretical 
properties of his estimator were later formally established using counting processes and martingale theory 
[16]. In this context, the sampled risk set at the failure time of a case i consists of the matched controls 
and the follow-up time is not involved in the partial likelihood. Therefore, Cox model estimation is 
equivalent to a simple logistic regression between cases and controls and the coefficient associated with a 
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covariate X(j) measures the ability of the covariate to discriminate between cases and controls (see [17] for 
details).  
 
Cox proportional hazard model for post-genome design. Consider the Cox model applied to the post-
genome cohort data (Ti,ΔGi) with Ti the follow-up time and ΔGi the difference of log-expression for the 
case-control pair i. The coefficients βg affecting the partial likelihood for a nested case-control design 
correspond to genes which are differentially expressed between cases and controls. This may includes 
genes which are constantly differentially expressed as well as genes whose expression changes before 
diagnosis. Therefore, the Cox model does not appear efficient to discriminate between these two 
behaviours.  
 
Cox model with time-varying coefficients. In the past twenty years, Cox model has generated a huge 
number of developments, which have provided important generalizations from the original model. In 
particular, the introduction of time-varying coefficients offers a more flexible framework [6] but its 
implementation in nested-case control studies remains limited. Liu et al [18] propose an estimator based 
on a kernel-weigthed local polynomial approach. Intuitively, the estimation of β(t) is based on the pairs 
with follow-up times in the close vicinity of t. The non-constant coefficients corresponds to genes with a 
non-multiplicative effect and do not specifically target genes whose expression changes over time. 
Therefore, the Cox model with time varying coefficients presents the same pitfalls as the classical Cox 
model: it does not provide a discrimination between the genes associated with cancer and the genes whose 
expression changes before diagnosis.  
 
Penalization procedures. In genome-wide studies, a penalization procedure is necessary to handle the 
large dimension covariates [3, 4]. It extracts a restricted set of genes which have the highest effect on the 
partial log-likelihood. Thus, on post-genome data, penalization would provide a restricted set of genes 
which offers the best discrimination between cases and controls. Therefore, genes whose expression 
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changes before diagnosis could be eliminated if they display a poorer discrimination ability than genes 
constantly differentially expressed. 
 
Summary. We have examined the relevance of classical semi-parametric models for the post-genome 
design. Additive hazard rate models are excluded in a context where a single measurement of gene 
expression is available. Multiplicative hazard rate models in a nested case-control design estimate the 
ability of a gene to discriminate between cases and controls, and do not appear efficient to specifically 
target genes whose expression changes over time.  
 
3.2  An alternative approach: parametrization of gene trajectories 
We propose a framework to directly handle the changes in gene expression during the carcinogenic 
process, if any, based on transcriptomics data from the post-genome cohort. Contrary to the models 
developed for genomics data in GWAS, transcriptomics are not considered as risk factors but as markers 
of the carcinogenic process and exposures.  
The expression of each gene is parameterized as a function of time to diagnosis and exposures. For each 
gene g and each case i: 
  
for some parametric function f(.|Θg). The exposures vector Ei includes lifestyle or environmental variables 
which affect gene expression, regardless of their association with cancer. Contrary to survival analysis 
models, the error term εi,g does not model the random occurrence of an event (diagnosis of cancer), but 
accounts for individual variations of gene expression. As described in Section 2.2, the controls are used as 
a reference to correct age and technical effects. Thus, we consider the following model for the case-
control differential gene expression ΔG:  
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for some parametric function h(.|Θg). The "difference of exposure" ΔEi for the case-control pair i can be 
equal to the difference for a continuous exposure, or to (Eicase, Eicontrol) for a categorical exposure. For each 
gene g, a p-value for the association between time to diagnosis and gene expression can be computed 
from model (4). Finally, a multiple testing procedure is implemented to control the type I error [19, 20].  
 
Model (4) represents a flexible framework which can include various biological assumptions. The 
following examples illustrate the potentialities of a gene-by-gene parameterization to explore functional 
changes in gene expression. The corresponding statistical models are provided in the Appendix. 
(a) Additive exposure effects and parametric time effect.  The differential expression of each gene 
is modelled as the sum of a linear effect of a vector of exposures and a carcinogenesis effect 
parameterized as a function of time. In particular the time effect could be modelled by a "hockey stick" 
function: the gene starts linearly over- or under-expressing at a certain time before diagnosis. Contrary to 
the Cox model, this model make the distinction between a constant case-control difference and changes in 
gene expression before diagnosis.  
(b) Non-parametric time effect. The unknown shape of the gene trajectory can be handled with a 
non-parametric estimator of the time effect. In particular, isotonic regression [21] allows testing of a 
monotonic effect of time on gene expression.  
(c) Exposure-driven functional model of carcinogenesis.  The gene-by-gene parametrization allows 
inclusion of more advanced hypotheses on gene-environment interactions. In particular, the assumption of 
carcinogenesis mechanisms driven by exposures [22] could be tested via a parameterization including 
interaction terms between time and carcinogen exposures.  
The implementation of gene-by-gene trajectory models requires choices based on epidemiological and 
biological knowledge. First of all, a set of relevant exposures that affect gene expression has to be 
determined. A cross-sectional study from an independent set of controls could provide a restricted set of 
exposures which present the strongest association with gene expression. Alternatively, meta-variables 
expressed as linear combinations of a large vector of exposures could be extracted by a principal 
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components analysis. Moreover, regarding breast cancer, a stratification of the cases based on cancer 
stage or receptor status would be necessary to account for heterogeneity of the carcinogenic process. A 
modeling including mechanisms common to all cases, as well as specific mechanisms for a given 
subgroup of cases could be implemented.  
 
4  Conclusion 
Exploration of the carcinogenic process on transcriptional outputs at the epidemiological level opens up 
new horizons in functional analysis and causal inference, and requires a new design together with 
adequate analysis procedures. Despite similarities with the more classical prospective GWAS, moving 
from genomics to transcriptomics addresses different goals and the relevance of canonical statistical 
methods for GWAS in these novel studies is questioned. Whereas prospective GWAS explore the effects 
of genomics and environmental variables on the time of occurrence of cancer via survival analysis models 
P[T|G,E], post-genome studies explore changes in the transcriptome during the carcinogenic process 
conditional on exposures: P[G|T,E]. 
The post-genome cohort includes transcriptomics measurements together with environmental exposures in 
a nested case-control prospective design. The transcriptional outputs observed in different individuals at 
different times before diagnosis, the trajectories, could be adjusted for the effects of exposures as a source 
of variation between individuals.  
The survival analysis models classically used in prospective GWAS, in particular the Cox model, have 
proven to be highly efficient for risk estimation and survival prediction. Nevertheless, we suggest that 
they are not appropriate to explore the functional changes in gene expression during the carcinogenic 
process. Indeed, in a genome-wide context, these models does not specifically target genes whose 
expression changes before diagnosis, but genes which offer the best discrimination between cases and 
controls. Therefore we propose to directly model the trajectory of the expression of each gene in a model 
including time to diagnosis and exposures. This flexible approach allows to model and test various 
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relationships between gene expression and exposures in the carcinogenic process, and offers a direct 
interpretation in terms of carcinogenesis mechanisms.  
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Figures 
 
 
Figure 1: Design of the NOWAC post-genome cohort   
 
 
Figure 2: Gene trajectory: hypothetical example. The first column presents the trajectory of a gene g for 
one individual. The second column displays the trajectories of g for five individuals (dotted lines), as well 
as measurements of gene expression at different times before diagnosis (dots). The measurements of gene 
expression isolated on the third column offer a good recovery of the trend in the trajectories.  
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Figure 3: From prospective GWAS to post-genome design.  
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Figure 4 
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Supplementary material 
We present the statistical models corresponding to the examples of gene-by-gene models described in 
Section 3.2. 
 
     (a) Additive exposure effects and parametric time effect. 
∆Gi,g = α
g
0 + ￿αg1,∆E(1)i ￿+ αg2TiI(Ti > tg) + ε￿i,g.
 
The coefficient α0g accounts for a constant difference between cases and controls along the follow-up 
time of the study, which can indicate changes in gene expression occurring earlier in the carcinogenic 
process, or exposure effects which have not been included in vector E(1). The coefficient vector α1g  
corresponds to the effects of exposures E(1) on the expression of gene g. Finally, α2g accounts for time 
effect:  a significantly non-zero coefficient α2g assesses an effect of carcinogenesis on gene g.  
 
      (b) Non-parametric time effect. The gene trajectory is estimated  through a non-parametric estimator 
ϕ of the time effect: 
∆Gi,g = α
g
0 + ￿αg1,∆E(1)i ￿+ ϕ(Ti) + ε￿i,g
 
      (c) Exposure-driven functional model of carcinogenesis. A model including interactions between 
the follow-up time and an exposure E(2) accounts for the involvement of a gene g in the carcinogenic 
process under the exposure E(2): 
∆Gi,g = α
g
0 + ￿αg1,∆E(1)i ￿+ ϕ(Ti) + E(2),casei ψ(Ti) + ε￿i,g
 
Function ϕ stands for a global effect of carcinogenesis on all cases, whereas ψ accounts for a driven by 
exposure effect, affecting the gene expression of pairs whose case is under exposure E(2).    
 
  
